Leerink Partnrs Issues Negative Outlook for REGN Earnings
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Leerink Partnrs lowered their Q2 2025 earnings per share estimates for shares of Regeneron Pharmaceuticals in a research report issued on Wednesday, June 11th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings per share of $7.71 for the quarter, down from […]
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Leerink Partnrs lowered their Q2 2025 earnings per share estimates for shares of Regeneron Pharmaceuticals in a research report issued on Wednesday, June 11th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings per share of $7.71 for the quarter, down from […]
